CSL’s headcount reduction and vaccine spinoff dragged shares down 9.5%, from A$271.32 at market close on 18 August to ...

Robert Kennedy Jr. signs recommendation eliminating mercury-based thimerosal from influenza vaccines, fulfilling anti-vaccine ...

Australian shares are set to open lower this morning after US stocks ended roughly flat overnight, as local traders await ...

Australian shares slipped off their all-time peak on Tuesday, dragged down by biotech major CSL’s steepest fall ...

Novavax, Inc. (NASDAQ:NVAX) is a biotechnology company focused on recombinant protein-based vaccines using nanoparticle and ...

CSL Limited is set to demerge its influenza vaccine division, CSL Seqirus, into a separate ASX-listed entity by the end of ...

Australia’s largest pharmaceutical company plans to spin off its Seqirus business into a separate ASX listing in the 2026 ...

CSL also said it would restart a multi-year share buyback program from FY26, beginning with A$750 million. Chief Executive ...

SYDNEY] Australian biotech giant CSL said that it will spin off its Seqirus vaccine business into a separately listed company ...

Biotech giant CSL has reported a 17% increase in full-year statutory profit to US$3 billion ($4.6 billion) and announced ...

Australian biotech giant CSL Ltd on Tuesday announced plans to demerge its influenza vaccine division, CSL Seqirus, and said it will lay off up to 15% of its workforce, after reporting a strong growth ...

New research projects funded to combat avian influenza in swine focus on vaccine development, transmission risks, and biosecurity measures.